"Viking Therapeutics' Breakthrough Weight-Loss Drug Sends Shares Soaring"

Viking Therapeutics' experimental weight-loss drug showed promising results in a mid-stage study, with patients experiencing an average weight loss of nearly 15%. This news caused the company's shares to more than double, reaching $85.05. The drug targets gut hormones and is seen as a potential competitive threat to existing weight-loss drugs from companies like Eli Lilly and Novo Nordisk. The positive results have generated significant interest from investors and analysts, with potential implications for the pharmaceutical industry and the stock market.